AUD 0.0
(0.0%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 | 4.93 Million AUD | -49.73% |
2023 | 9.81 Million AUD | -13.57% |
2022 | 11.35 Million AUD | 94.51% |
2021 | 5.83 Million AUD | 68.05% |
2020 | 3.47 Million AUD | 176.63% |
2019 | 1.25 Million AUD | -58.39% |
2018 | 3.01 Million AUD | 27.57% |
2017 | 2.36 Million AUD | 19.67% |
2016 | 1.97 Million AUD | -68.68% |
2015 | 6.31 Million AUD | -26.48% |
2014 | 8.58 Million AUD | 60.61% |
2013 | 5.34 Million AUD | -32.79% |
2012 | 7.95 Million AUD | -14.11% |
2011 | 9.26 Million AUD | -8.54% |
2010 | 10.12 Million AUD | -14.94% |
2009 | 11.9 Million AUD | 42.42% |
2008 | 8.35 Million AUD | 0.0% |
2007 | - AUD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 2.07 Million AUD | 0.0% |
2024 FY | 4.87 Million AUD | -50.34% |
2024 Q4 | 2.31 Million AUD | 0.0% |
2023 Q2 | 5.71 Million AUD | 0.0% |
2023 Q4 | 4.19 Million AUD | 0.0% |
2023 FY | 9.81 Million AUD | -13.57% |
2022 Q2 | 6.16 Million AUD | 0.0% |
2022 Q4 | 5.43 Million AUD | 0.0% |
2022 FY | 11.35 Million AUD | 94.51% |
2021 Q4 | 3.66 Million AUD | 0.0% |
2021 Q2 | 2.21 Million AUD | 0.0% |
2021 FY | 5.83 Million AUD | 68.05% |
2020 FY | 3.47 Million AUD | 176.63% |
2020 Q4 | 1.69 Million AUD | 0.0% |
2020 Q2 | 1.83 Million AUD | 0.0% |
2019 Q2 | 673.05 Thousand AUD | 0.0% |
2019 FY | 1.25 Million AUD | -58.39% |
2019 Q4 | 1.92 Million AUD | 0.0% |
2018 Q4 | 1.79 Million AUD | 0.0% |
2018 Q2 | 1.21 Million AUD | 0.0% |
2018 FY | 3.01 Million AUD | 27.57% |
2017 Q2 | 822.45 Thousand AUD | 0.0% |
2017 FY | 2.36 Million AUD | 19.67% |
2017 Q4 | 767.14 Thousand AUD | 0.0% |
2016 Q2 | 1.16 Million AUD | 0.0% |
2016 FY | 1.97 Million AUD | -68.68% |
2016 Q4 | 783.98 Thousand AUD | 0.0% |
2015 FY | 6.31 Million AUD | -26.48% |
2015 Q4 | 6.77 Million AUD | 0.0% |
2015 Q2 | 3.91 Million AUD | 0.0% |
2014 Q4 | 4.06 Million AUD | 0.0% |
2014 Q2 | 3.97 Million AUD | 0.0% |
2014 FY | 8.58 Million AUD | 60.61% |
2013 Q3 | 1.17 Million AUD | -45.47% |
2013 Q2 | 2.15 Million AUD | 39.64% |
2013 FY | 5.34 Million AUD | -32.79% |
2013 Q1 | 1.54 Million AUD | 0.0% |
2013 Q4 | 2.34 Million AUD | 100.0% |
2012 Q1 | 2.06 Million AUD | 0.0% |
2012 Q4 | 1.54 Million AUD | 0.0% |
2012 FY | 7.95 Million AUD | -14.11% |
2012 Q2 | 1.54 Million AUD | -25.22% |
2012 Q3 | 1.54 Million AUD | 0.0% |
2011 Q4 | 2.06 Million AUD | 0.0% |
2011 Q1 | 2.25 Million AUD | 0.0% |
2011 Q2 | 2.06 Million AUD | -8.72% |
2011 Q3 | 2.06 Million AUD | 0.0% |
2011 FY | 9.26 Million AUD | -8.54% |
2010 Q3 | 2.25 Million AUD | 0.0% |
2010 FY | 10.12 Million AUD | -14.94% |
2010 Q1 | 2.81 Million AUD | 0.0% |
2010 Q2 | 2.25 Million AUD | -19.63% |
2010 Q4 | 2.25 Million AUD | 0.0% |
2009 Q1 | -2.08 Million AUD | 0.0% |
2009 FY | 11.9 Million AUD | 42.42% |
2009 Q4 | 2.81 Million AUD | 0.0% |
2009 Q2 | 2.81 Million AUD | 234.55% |
2009 Q3 | 2.81 Million AUD | 0.0% |
2008 FY | 8.35 Million AUD | 0.0% |
2008 Q1 | - AUD | 0.0% |
2008 Q3 | -2.08 Million AUD | 0.0% |
2008 Q2 | -2.08 Million AUD | 0.0% |
2008 Q4 | -2.08 Million AUD | 0.0% |
2007 FY | - AUD | 0.0% |
2007 Q4 | - AUD | 0.0% |
2007 Q3 | - AUD | 0.0% |
2007 Q2 | - AUD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
EZZ Life Science Holdings Limited | 39.57 Million AUD | 87.534% |
Anatara Lifesciences Ltd | 710.21 Thousand AUD | -594.621% |
Zelira Therapeutics Limited | 5.94 Million AUD | 17.066% |
Biome Australia Limited | 7.91 Million AUD | 37.642% |
Orthocell Limited | 15.36 Million AUD | 67.902% |
Imugene Limited | 135.09 Million AUD | 96.348% |
Noxopharm Limited | 7 Million AUD | 29.526% |
PYC Therapeutics Limited | 60.91 Million AUD | 91.902% |
Chimeric Therapeutics Limited | 19.76 Million AUD | 75.043% |
Prescient Therapeutics Limited | 10.89 Million AUD | 54.735% |
Proteomics International Laboratories Limited | 892.14 Thousand AUD | -452.973% |
Cynata Therapeutics Limited | 11.12 Million AUD | 55.65% |
CSL Limited | 7.56 Billion AUD | 99.935% |
Arovella Therapeutics Limited | 10.78 Million AUD | 54.259% |
Bio-Gene Technology Limited | 2.76 Million AUD | -78.678% |
Clinuvel Pharmaceuticals Limited | 31.29 Million AUD | 84.237% |
Starpharma Holdings Limited | 22.81 Million AUD | 78.378% |
Nanollose Limited | 12.5 Thousand AUD | -39363.347% |
Memphasys Limited | 3.67 Million AUD | -34.116% |
Invex Therapeutics Ltd | 3.34 Million AUD | -47.444% |
NeuroScientific Biopharmaceuticals Limited | 1.96 Million AUD | -151.031% |
Amplia Therapeutics Limited | 8.43 Million AUD | 41.519% |
Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -719.732% |
Island Pharmaceuticals Limited | 4.12 Million AUD | -19.585% |
Race Oncology Limited | 14.77 Million AUD | 66.6% |
Nyrada Inc. | 4.55 Million AUD | -8.301% |
Telix Pharmaceuticals Limited | 269.26 Million AUD | 98.168% |
Dimerix Limited | 25.64 Million AUD | 80.762% |
PharmAust Limited | 6.65 Million AUD | 25.893% |
Immutep Limited | 42.87 Million AUD | 88.494% |
Clarity Pharmaceuticals Ltd | 56.3 Million AUD | 91.239% |
Alterity Therapeutics Limited | 23.4 Million AUD | 78.923% |
BTC Health Limited | -1.03 Million AUD | 574.847% |
Acrux Limited | 8.55 Million AUD | 42.3% |
Neuren Pharmaceuticals Limited | 32.69 Million AUD | 84.912% |
Biotron Limited | 5.11 Million AUD | 3.47% |
Tissue Repair Ltd | 6.66 Million AUD | 26.002% |
AdAlta Limited | 6.76 Million AUD | 27.124% |
Radiopharm Theranostics Limited | 299.22 Thousand AUD | -1548.68% |
Hexima Limited | 1 Million AUD | -389.052% |
AnteoTech Limited | 12.18 Million AUD | 59.52% |
Paradigm Biopharmaceuticals Limited | 65.1 Million AUD | 92.422% |
Recce Pharmaceuticals Ltd | 21.68 Million AUD | 77.25% |
Avecho Biotechnology Limited | 4.54 Million AUD | -8.534% |
Actinogen Medical Limited | 22.77 Million AUD | 78.335% |
Immuron Limited | 9.13 Million AUD | 46.013% |
Argenica Therapeutics Limited | 8.26 Million AUD | 40.341% |